The Oncology Care Model (OCM) has set off a ripple of change in cancer care that extends beyond the patients who are in the model, said David Ortiz, OCM program director at Montefiore Einstein Center for Cancer Care.
The Oncology Care Model (OCM) has set off a ripple of change in cancer care that extends beyond the patients who are in the model, said David Ortiz, OCM program director at Montefiore Einstein Center for Cancer Care.
Transcript
Are physicians who are in OCM practices getting more used to this new way of delivering care? How have they adjusted?
I think OCM has been that ripple, that first ripple, in a wave of events that now are kind of connected. So, OCM, now, is expanding to a more consistent language. So, everything is about value-based, now everything is tied to quality. It always was, but I think now the stamp of OCM really gave us the opportunity to talk more about it on a more consistent basis and engage the providers.
Most of the clinicians, like the mid-levels and the nurses, they’ve really been like our champions for this process and then we’ve instilled navigators who are seasoned veteran—they’re nurses who’ve already earned their respect long ago. That kind of all mixed together has been a great wave.
Are patients noticing a difference in the way care is delivered to them under OCM?
I think that we’re making incremental changes. And I think the patients that we are focused on typically are the sickest, the poorest, and the ones in most need. However, we’re setting the tone for what we really need to do for every patient. And I think you’re starting to see that. So, when a navigator introduces, you know like, “Hi, my name is Eileen, I’m here to navigate,” there are people right beside like, “Where’s my Eileen?” And that’s what we’re using to justify trying to expand.
I think that’s one of the harder pieces to that is we have to stay focused because we have to produce results, but we need to really radiate out to everyone in need. So, we’re starting to see an even balance of patients who are non-OCM, as well as OCM patients, being navigated, because the need outweighs the program itself.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More